This article is part of a Chronicle. See more from this Chronicle
Kristina Nordlander, Stephen Spinks, Feb 24, 2009
In the presentation of its Preliminary Report on the pharmaceutical sector inquiry, the European Commission attempted to perform a delicate balancing of competition and International Property (“IP”) law. While the Commission went out of its way repeatedly to state that the value of IP rights in general, and patents in particular, are not in dispute in the sector inquiry
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.143.228.40
Please verify email or join us to access premium content!